ANNX - Annexon, Inc.
IEX Last Trade
5.24
-0.020 -0.382%
Share volume: 14,020
Last Updated: Thu 26 Dec 2024 08:30:14 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$5.26
-0.02
-0.38%
Fundamental analysis
27%
Profitability
25%
Dept financing
20%
Liquidity
50%
Performance
25%
Performance
5 Days
-0.95%
1 Month
-1.13%
3 Months
-14.54%
6 Months
12.47%
1 Year
18.59%
2 Year
3.98%
Key data
Stock price
$5.24
DAY RANGE
$5.09 - $5.28
52 WEEK RANGE
$4.20 - $8.40
52 WEEK CHANGE
$14.44
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Douglas Love
Region: US
Website: annexonbio.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: annexonbio.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain-baré syndrome. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Recent news